Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niagen in Long COVID
NCT04809974Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nicotinamide riboside in post-acute sequelae of SARS-CoV-2 infection (PASC), sponsored by Massachusetts General Hospital. Started Aug 2021; status: completed.
02
Drugs
nicotinamide riboside
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT04809974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04809974.